Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
VioQuest Pharmaceuticals is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With over 1,975 employees, it has a presence, through its 13 affiliates in Europe and United States.
Insite Vision is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.